{
  "ticker": "EMD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960363",
  "id": "02960363",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250620",
  "time": "0941",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250620/pdf/06ky2812phwtbl.pdf",
  "summary": "- **Key Highlight**: Emyria's Chief Scientific Officer presenting at Psychedelic Science 2025, highlighting the reimbursement agreement with Medibank for PTSD treatment.  \n- **Investor Update**: Webinar planned to detail the Medibank reimbursement model (to be announced next week).  \n\nNo material trading or capital markets information identified.",
  "usage": {
    "prompt_tokens": 1565,
    "completion_tokens": 70,
    "total_tokens": 1635,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-19T23:59:36.303933"
}